COST – EFFECTIVENESS ANALYSIS OF USING ANTIDIABETIC IN OUTPATIENT WITH TYPE 2 DIABETES MELLITUS
DOI:
https://doi.org/10.47701/icohetech.v4i1.3407Keywords:
antidiabetic, acer, cost-effectiveness, diabetes mellitus type 2, insulinAbstract
Type 2 diabetes Mellitus is a chronic disease that requires lifelong treatment. In the course of the disease, if blood sugar levels are not controlled, it can lead to complications of other diseases. The variety of antidiabetic drugs used in therapy can lead to differences in the cost effectiveness of therapy. The aims of this study is to analyze the cost-effectiveness of antidiabetic therapy in outpatients at Dr. Moewardi Hospital. Data collection in this study was carried out retrospectively using medical records of outpatients with type 2 diabetes mellitus and billing data from the hospital The data obtained were then presented descriptively and the ACER value was calculated for the 2 most widely used drug groups. The results of this study showed that 30 patients received a combination of Insulin Analog (Basal) + Insulin Analog (Prandial/Premixed) and and 11 patients received Insulin Analog (Basal/ Prandial/ Premixed). The percentage effectiveness of combination therapy Insulin Analog (Basal) + Insulin Analog (Prandial/ Premixed) was higher than Insulin Analog (Basal/ Prandial/ Premixed) (83.33 vs 72.72). The ACER value of Insulin Analog (Basal) + Insulin Analog (Prandial/ Premixed) (IDR 13.802,42) is lower than Insulin Analog (Basal/ Prandial/ Premixed) (IDR 18.356). Based on the cost effectiveness table, the combination of Insulin Analog (Basal) + Insulin Analog (Prandial / Premixed) is more effective so that the combination of Insulin Analog (Basal) + Insulin Analog (Prandial / Premixed) is more cost effective than Insulin Analog (Basal / Prandial / Premixed).
References
Andayani, Tri M. (2013). Farmakoekonomi: Prinsip dan Metodelogi. Yogyakarta: Bursa Ilmu Karangkajen.
Arania, Resti, Triwahyuni, Tusy, Prasetya, Toni, & Cahyani, Sekar Dwi. (2021). Hubungan Antara Pekerjaan Dan Aktivitas Fisik Dengan Kejadian Diabetes Mellitus Di Klinik Mardi Waluyo Kabupaten Lampung Tengah. Jurnal Medika Malahayati, 5(3), 163–169. https://doi.org/10.33024/jmm.v5i3.4110
Association, American Diabetes. (2022). Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers. Clinical Diabetes : A Publication of the American Diabetes Association, 40(1), 10–38. https://doi.org/10.2337/cd22-as01
Depkes. (2008). Pedoman Pengendalian Diabetes Melitus dan Penyakit Metabolik (p. 82). p. 82. Retrieved from file:///D:/ebook/dsa664.pdf
Dewi Prasetyani, Sodikin. (2017). Analisis Faktor Yang Mempengaruhi Kejadian Diabetes Melitus (Dm) Tipe 2., 2(2), 1–9.
Escobar, Carlos, Morales, Cristóbal, Capel, Margarita, Simón, Susana, Pérez-Alcántara, Ferran, & Pomares, Elisenda. (2022). Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study. BMC Health Services Research, 22(1), 1–9. https://doi.org/10.1186/s12913-022-07567-5
Finkelstein, E. A., Chay, J., & Bajpai, S. (2014). The economic burden of self-reported and undiagnosed cardiovascular diseases and diabetes on Indonesian households. PLoS ONE, 9(6). Retrieved from https://doi.org/10.1371/journal.pone.0099572
Fitria, Najmiatul, Andela, Mila, Syaputri, Yolanda Zazna, & Nasif, Hansen. (2023). Analisis Efektivitas Biaya Penggunaan Metformin-GlimepirideTerhadap Penurunan Kadar Gula Darah Puasa Pada Pasien Diabetes Mellitus Tipe 2 di RS Universitas Andalas. Jurnal Sains Farmasi & Klinis, 9(sup), 202. https://doi.org/10.25077/jsfk.9.sup.202-207.2022
Gonçalves, Ana Carolina Oliveira, Cazarim, MaurÃlio De Souza, Sanches, Cristina, Pereira, Leonardo Regis Leira, Camargos, Ana Márcia Tomé, Aquino, Jéssica Azevedo, & Oliveira Baldoni, Andre. (2019). Cost-effectiveness analysis of a pharmacotherapeutic empowerment strategy for patients with type 2 diabetes mellitus. BMJ Open Diabetes Research and Care, 7(1). https://doi.org/10.1136/bmjdrc-2018-000647
Isnani, Nazhipah, Muliyani, Muliyani, Zaini, Muhammad, & Arif Riyadi, Muhammad. (2021). Analisis Efektivitas Biaya (Cost-Effectiveness) Penggunaan Antidiabetes Oral Kombinasi Pada Pasien Diabetes Melitus Tipe Ii Rawat Jalan Di Rsud Dr. H. Moch. Ansari Saleh Banjarmasin. Jurnal Insan Farmasi Indonesia, 4(1), 103–110. https://doi.org/10.36387/jifi.v4i1.683
J. Lyle Bootman, Raymond J. Townsend, William F. McGhan. (2005). Principles of Pharmacoeconomics. USA: Harvey Whitney Books Company.
Javanbakht, Mehdi, Baradaran, Hamid R., Mashayekhi, Atefeh, Haghdoost, Ali Akbar, Khamseh, Mohammad E., Kharazmi, Erfan, & Sadeghi, Aboozar. (2011). Cost-of-illness analysis of type 2 diabetes mellitus in Iran. PLoS ONE, 6(10), 1–7. https://doi.org/10.1371/journal.pone.0026864
Kementerian Kesehatan RI. (2020). Infodatin tetap produktif, cegah, dan atasi Diabetes Melitus 2020. Pusat Data Dan Informasi Kementerian Kesehatan RI, pp. 1–10.
